Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Short term Debt (2018 - 2019)

10x Genomics (TXG) has disclosed Short term Debt for 2 consecutive years, with $9.9 million as the latest value for Q4 2019.

  • Quarterly Short term Debt rose 136.02% to $9.9 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2019, up 136.02% year-over-year, with the annual reading at $9.9 million for FY2019, 136.02% up from the prior year.
  • Short term Debt hit $9.9 million in Q4 2019 for 10x Genomics, up from $7.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $9.9 million in Q4 2019 to a low of $4.2 million in Q4 2018.